Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.62 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | MMP2 | P08253 | 1/20 | 0.54 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.51 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.51 |
| ▸ | LTA4H | P09960 | 5/20 | 0.49 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARD | Q03181 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.47 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4842616 | 0.86 | FFAR1 (0.61) | L3MBTL1FFAR1LMNAMMP2FFAR4 | |
| SCHEMBL12117110 | 0.85 | L3MBTL1 (0.67) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL854425 | 0.83 | L3MBTL1 (0.65) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL927153 | 0.83 | FFAR1 (0.53) | L3MBTL1FFAR1TSHRFFAR4 | |
| SCHEMBL8277617 | 0.81 | L3MBTL1 (0.68) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| Hydrochloric Acid SCHEMBL25291520 | 0.81 | PLA2G4B (0.53) | L3MBTL1FFAR1LMNALTA4HPPARA | |
| SCHEMBL2198008 | 0.81 | L3MBTL1 (0.67) | L3MBTL1FFAR1LMNAMMP2LTA4H | |
| SCHEMBL1249954 | 0.81 | ALOX15 (0.61) | FFAR1MAOBTSHRPPARGPPARD | |
| SCHEMBL1668551 | 0.81 | LTA4H (0.52) | L3MBTL1LMNAKEAP1NFE2L2LTA4H | |
| SCHEMBL7973439 | 0.80 | KEAP1 (0.67) | KEAP1NFE2L2LTA4HMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3476829-B1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | UNIV FUDAN (CN) | 2021-12-15 | — | — | EP | disclosed |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-12-01 | — | — | US | disclosed |
| US-20200239411-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | UNIV FUDAN (CN) | 2020-07-30 | — | — | US | disclosed |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | FUDAN UNIVERSITY (CN) | 2020-05-12 | — | — | US | disclosed |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | FUDAN UNIVERSITY (CN) | 2019-08-15 | — | — | US | disclosed |
| EP-3476829-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF, AND MANUFACTURING AND APPLICATION OF SAME | Fudan University (CN) | 2019-05-01 | — | — | EP | disclosed |
| CN-102746214-A | Novel indoline compounds | FOURNIER LAB SA | 2012-10-24 | — | — | CN | disclosed |
| US-7872021-B2 | LXR receptor modulators | LABORATORIES FOURNIER S.A. (FR) | 2011-01-18 | — | — | US | disclosed |
| US-7465811-B2 | Indoline compounds | LABORATOIRES FOURNIER S.A. (FR) | 2008-12-16 | — | — | US | disclosed |
| US-20080119465-A1 | Novel Indoline Compounds | LABORATORIES FOURNIER S.A. (FR) | 2008-05-22 | — | — | US | disclosed |
| US-20070099960-A1 | LXR receptor modulators | LABORATOIRES FOURNIER S.A. (FR) | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099960-A1 | LXR receptor modulators | NR1H2, NR1H3, PPARD | L3MBTL1 3947/4885FFAR1 40/4885LMNA 1809/4885 |
| US-20080119465-A1 | Novel Indoline Compounds | GPR119, INSR, IRS1 | L3MBTL1 1493/4885FFAR1 55/4885LMNA 1943/4885 |
| US-20200239411-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | L3MBTL1 4601/4885FFAR1 849/4885LMNA 3458/4885 |
| US-20190248737-A1 | BIARYL UREA DERIVATIVE OR SALT THEREOF AND PREPARATION PROCESS AND USE FOR THE SAME | RORC, RORB, RORA | L3MBTL1 4618/4885FFAR1 702/4885LMNA 3412/4885 |
| US-10647665-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | L3MBTL1 4618/4885FFAR1 702/4885LMNA 3412/4885 |
| US-10851050-B2 | Biaryl urea derivative or salt thereof and preparation process and use for the same | RORC, RORB, RORA | L3MBTL1 4601/4885FFAR1 849/4885LMNA 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.